Giant in the Shadows: The Billions, Battles, and Rebrand of Cencora
pplpod · pplpod
Audio is streamed directly from the publisher (content.rss.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
In this episode, we pull back the curtain on Cencora, the company formerly known as AmerisourceBergen. Despite handling nearly 20% of all pharmaceuticals sold in the United States, this industry titan often operates behind the scenes. We trace its origins from the 2001 merger of AmeriSource and Bergen Brunswig to its evolution into a global powerhouse with over $300 billion in annual revenue.
We dig deep into the controversies that have plagued the distributor, including its central role in the American Opioid Epidemic, which led to a historic $26 billion settlement with states and local governments. You’ll hear about the "PFS Program," a civil fraud scheme involving the repackaging of cancer drugs that resulted in an $885 million payout, and the company's unusual agreement with the U.S. government to distribute Remdesivir during the early days of the COVID-19 pandemic.
Finally, we discuss the company's 2023 strategic rebrand to "Cencora" and its continuing challenges, including a major 2024 cyber incident exposing patient data. Join us as we explore how one of the world's largest pharmaceutical companies navigates profit, legal peril, and public health.